Scenario | Intervention | Baseline | 2020 coverage targets | 2025 coverage targets | 2030 coverage targets |
---|---|---|---|---|---|
1. Sustain | All | Maintain coverage of all interventions at 2011–2013 levels | |||
2. Accelerate | Vector control LLIN IRS | Means of 2011–2013 country-specific coverage | 80% with LLIN replaced every 3 years | 90% with LLIN replaced every 2 years | Maintain coverage |
Other measures | 10% additional coverage with complementary control measures for resistance management | ||||
SMC | 0% | 80% | 95% | Maintain | |
IPTp | 0% | 80% | 90% | Maintain | |
Blood tests, using RDTs or microscopy | 20% | 90% | |||
10% G6PD testing | 90% | ||||
Treatment of uncomplicated cases | 2013 country-specific coverage | 90% at public facilities, 50% in communities | . | 75% community based treatment | |
Treatment of severe cases | 100% hospitalised cases treated with quinine | 100% hospitalised cases treated with injectable artesunate | 50% severe cases with rectal artesunate in communities | 75% severe cases with rectal artesunate in communities |
The 2011–2013 levels were assumed until 2015 and were then scaled up; vector control modelled as LLIN.
LLIN, long-lasting insecticidal treated nets; IRS, indoor residual spraying; LSM, larval source management; SMC, seasonal malaria chemoprevention; IPTp, intermittent preventive treatment of malaria in pregnant women; RDT, rapid diagnostic test; G6PD, glucose-6-phosphate dehydrogenase deficiency.